US4935223A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Labeled cells for use in imaging
Assignee: The University of Texas System
•
Filing: 1988-08-04
•
Granted: 1990-06-19
•
Expires: 2008-08-04
Abstract
Abstract A process is provided for the labeling of viable eucaryotic cells. The process includes the steps of collecting, separating, and introducing a quantity of first type cells into a non-toxic media suitable to conduct an electric field. A labeling material is added to this media. The media containing the first type cells and the labeling material is pulsed for a period of time with an electric field, sufficient to render the cell membranes permeable so that the labeling material permeates the cells and becomes trapped therein upon cessation of the pulsing to produce labeled cells. Also provided is a process for diagnostically imaging pathological sites in a patient. This process contains the additional steps of administering the labeled cells to a patient and monitoring the localization of the labeling material in the patient to image the locus of a specific pathosis.
Inventors
- 👤 William Phillips
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 05:06
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/1203; A61K2123/00
Claims Analysis
Total Claims: 41
Claim 1
Independent Claim
142 words
A process for diagnostically imaging pathological sites, the process comprising the steps of: (a) collecting an amount of living cells; (b) separating from said amount a plurality of first type cells, (c) introducing a quantity of said first-type cells into a non-toxic media, said media being electrically conductive; (d) introducing a labeling material which is x-ray opaque, gamma particle emitting, paramagnetic, proton emitting or positron emitting into said media; (e) pulsing said media for a period of time with an electric field sufficient to render membranes of said first type cells permeable so that said labeling material permeates the cells and becomes trapped therein upon cessation of the pulsing to produce labeled cells; (f) administering said labeled cells to a patient; and (g) monitoring localization of label in said labeled cells in the patient to image the locus of a specific pathosis.
Claim 2
Dependent Claim
142 words
A process for diagnostically imaging pathological sites, the process comprising the steps of: (a) collecting an amount of living cells; (b) separating from said amount a plurality of first type cells, (c) introducing a quantity of said first-type cells into a non-toxic media, said media being electrically conductive; (d) introducing a labeling material which is x-ray opaque, gamma particle emitting, paramagnetic, proton emitting or positron emitting into said media; (e) pulsing said media for a period of time with an electric field sufficient to render membranes of said first type cells permeable so that said labeling material permeates the cells and becomes trapped therein upon cessation of the pulsing to produce labeled cells; (f) administering said labeled cells to a patient; and (g) monitoring localization of label in said labeled cells in the patient to image the locus of a specific pathosis.
Claim 3
Dependent Claim
24 words
The process of claim 1 wherein said first type cells are selected from the group consisting of: leukocytes, erythrocytes, T-cell lymphocytes, eosinophils and platelets.
Claim 4
Dependent Claim
20 words
The process of claim 1 wherein said first type cells demonstrate a chemotactic affinity for specific loci within the patient.
Claim 5
Dependent Claim
18 words
The process of claim 1 wherein said first type cells are of a type involved in immune responses.
Claim 6
Dependent Claim
20 words
The process of claim 1, wherein said first type cells demonstrate a chemotactic affinity to aggregate at a specific pathosis.
Claim 7
Dependent Claim
11 words
The process of claim 1 wherein said media is a suspension.
Claim 8
Dependent Claim
15 words
The process of claim 1 wherein said electric field is generated by an electroporation device.
Claim 9
Dependent Claim
12 words
The process of claim 1 wherein said media is normal saline solution.
Claim 10
Dependent Claim
11 words
The process of claim 1 wherein said media is platelet-free plasma.
Claim 11
Dependent Claim
19 words
The process of claim 1 wherein said lableling material comprises 99m Tc, 95m Tc, 123 I or 67 Ga.
Claim 12
Dependent Claim
23 words
The process of claim 1 wherein said amount of living cells is collected from blood of a patient to be administered labeled cells.
Claim 13
Dependent Claim
16 words
The process of claim 1 wherein monitoring localization of the label involves single photon emission tomography.
Claim 14
Dependent Claim
14 words
The process of claim 1 wherein monitoring localization of label involves positron emission tomography.
Claim 15
Dependent Claim
14 words
The process of claim 1 wherein monitoring localization of label involves magnetic resonance imaging.
Claim 16
Dependent Claim
14 words
The process of claim 1 wherein monitoring localization of label involves standard x-ray imaging.
Claim 17
Dependent Claim
16 words
The process of claim 1 wherein administering of said labeled cells is done by intravenous injection.
Claim 18
Dependent Claim
16 words
The process of claim 1 wherein administering of said labeled cells is done by intrathecal injection.
Claim 19
Dependent Claim
16 words
The process of claim 1 wherein administering of said labeled cells is done by intraperitoneal injection.
Claim 20
Dependent Claim
16 words
The process of claim 1 wherein administering of said labeled cells is done by intraarterial injection.
Claim 21
Dependent Claim
12 words
The process of claim 1 wherein said living cells are human cells.
Claim 22
Dependent Claim
26 words
The process of claim 1 wherein said labeling material of step (d) is introduced into said media prior to the introduction of said first type cells.
Claim 23
Dependent Claim
37 words
The process of claim 1 wherein said labeled cells of step (e) are removed from said media and placed in a media suitable for administration to a patient prior to administering said labeled cells to a patient.
Claim 24
Dependent Claim
15 words
The process of claim 1 wherein said first type cells are interferon-stimulated killer T-cell lymphocytes.
Claim 25
Dependent Claim
15 words
The process of claim 23 wherein the killer T-cell lymphocytes are employed to image neoplasms.
Claim 26
Dependent Claim
14 words
The process of claim 1 wherein said first type cells are helper T-cell lymphocytes.
Claim 27
Dependent Claim
16 words
The process of claim 25 wherein the helper T-cell lymphocytes are employed to image autoimmune-disease tissue.
Claim 28
Dependent Claim
12 words
The process of claim 1 wherein said first type cells are eosinophils.
Claim 29
Dependent Claim
14 words
The process of claim 27 wherein the eosinophils are employed for imaging of parasites.
Claim 30
Dependent Claim
12 words
The process of claim 1 wherein said first type cells are platelets.
Claim 31
Dependent Claim
13 words
The process of claim 29 wherein the platelets are employed to image emboli.
Claim 32
Dependent Claim
12 words
The process of claim 1 wherein said first type cells are leukocytes.
Claim 33
Dependent Claim
15 words
The process of claim 31 wherein the leukocytes are employed to image localized occult absesses.
Claim 34
Dependent Claim
12 words
The process of claim 1 wherein said first type cells are erythrocytes.
Claim 35
Dependent Claim
14 words
The process of claim 33 wherein the erythrocytes are employed to image internal hemorrhages.
Claim 36
Dependent Claim
12 words
The process of claim 1 wherein said labeling material is a radiopharmaceutical.
Claim 37
Dependent Claim
26 words
The method of claim 35 wherein the radiopharmaceutical is selected from the group consisting of: 99m Tc-glucoheptonate, 99m Tc-methylene diphosphonate, 99m Tc-pyrophosphate, and 67 gallium citrate.
Claim 38
Dependent Claim
14 words
The process of claim 1 wherein said labeling material is a stable paramagnetic isotope.
Claim 39
Dependent Claim
11 words
The process of claim 37 wherein said labeling material is gadolinium.
Claim 40
Dependent Claim
14 words
The process of claim 1 wherein monitoring localization of label involves computerized axial tomography.
Claim 41
Dependent Claim
30 words
The process of claim 39 wherein said labeled cells are administered to an animal and the localization of said cells is monitored to image the locus of a specific pathosis.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-06-18 | 1993-12-18 | 1994-06-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-06-18 | 1997-12-18 | 1998-06-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-06-18 | 2001-12-18 | 2002-06-19 | $7700.00 | Window Closed / Lapsed |